**BUY** 

Voltas

# UCP margins surprise; risk reward attractive

Consumer Durables 

Result Update 
May 09, 2025

Voltas clocked a healthy Q4 performance (revenue up 13% YoY at Rs47.7br; largely inline) backed by stellar execution in the UCP business (up 17% YoY) with a standout EBIT margin of ~10% (much ahead of our estimate of 7.1%) owing to better product mix and improving scale benefits. However, it missed our PAT estimate by ~8% due to the projects business turning negative. While April was muted given unseasonal rains and the delay in onset of Summer-25 impacting both, primary/secondary sales, the mgmt. remains hopeful of a recovery in May–Jun (expects a longer and stronger tail to the summer season). We cut FY26E/FY27E PAT by ~9-10%, given the near-term uncertainty in Summer-2025. At current valuations and with UCP P/sales at 3.1x (below 10Y average of 3.6x), the stock trades at attractive valuations (refer to our IC: *Cooling curve turning vertical*); hence, we retain BUY while revising down our TP by ~9% to Rs1,450, implied at ~41x FY27 PER and Voltbek at Rs33/sh.

# Q4: UCP division surprises on the margin front

Consolidated revenue stood at Rs47.7bn (up 13% YoY, at a ~2 miss on consensus/Emkay estimates) for Voltas in Q4FY25. The UCP division's revenue growth was robust at ~17% YoY, with a phenomenal EBIT margin of ~10% in Q4 (much ahead of Emkay estimate of ~7.1%) owing to better product mix. EMPS (projects) growth was flattish at ~4%, with margins turning negative in Q4 owing to Rs400mn contingent provision created during Q4 on account of payment delays for international projects. Consol EBITDA for FY25 stood at Rs11.1bn (up 135%YoY), with margin at 7.2% (miss on Emkay of ~7.4%)

## **Earnings Call KTAs**

i) During FY25, Voltas sold ~2.5mn RAC units in FY25, retaining market leadership with ~19% market share; industry volume estimated at ~13-14mn units. ii) UCP margins saw improvement on a better product mix (premium 5-star RACs, industrial air coolers), scale benefits, and labor/productivity gains. iii) While April was muted, with unseasonal rains and a delayed start to the summer impacting both, primary and secondary sales, the management remains hopeful of a recovery in May-Jun (expects a longer and stronger tail to the summer season) partially offsetting the April weakness. iv) No significant price hikes were taken in Q4. Also, no major discounting was undertaken by peers, although elevated channel inventory is a concern due to early stocking in anticipation of a strong summer and supply constraints. v) CAC demand is expected to remain strong in FY26, driven by higher capex, better AMC conversion, and strong retrofit demand, while Com Ref saw a weak FY25 due to QCO-related issues, though recovery is expected in FY26 as factory ramp-up normalizes and order pipeline improves. vi) A Rs400mn provision was created during Q4 on account of payment delays beyond contractual timelines, made for international receivables (mainly UAE and Saudi projects). vii) Voltas Beko YTD market share is ~15.3% in semi-automatic washing machines, making it the #2 in India, while refrigerator share is up, at 5.3%; plans to fully localize refrigerator manufacturing.

<b>Voltas: Financial S</b>	napshot (Cor	nsolidated)			
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	94,988	124,812	154,128	164,731	184,475
EBITDA	5,724	4,746	11,162	11,814	13,701
Adj. PAT	3,789	2,520	8,414	9,406	11,200
Adj. EPS (Rs)	11.5	7.6	25.4	28.4	33.9
EBITDA margin (%)	6.0	3.8	7.2	7.2	7.4
EBITDA growth (%)	(16.0)	(17.1)	135.2	5.8	16.0
Adj. EPS growth (%)	(24.8)	(33.5)	233.9	11.8	19.1
RoE (%)	6.9	4.5	13.6	13.7	14.6
RoIC (%)	21.1	13.2	29.2	22.4	22.4
P/E (x)	106.8	160.6	48.1	43.0	36.1
EV/EBITDA (x)	67.1	80.6	33.7	31.7	27.1
P/B (x)	7.4	7.0	6.2	5.6	5.0
FCFF yield (%)	-	1.2	(1.1)	0.3	0.7

Source: Company, Emkay Research

+91-22-66121281 This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and dov

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.



#### CMP (Rs): 1,223 | TP (Rs): 1,450

Target Price – 12M	Mar-26
Change in TP (%)	(9.4)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	18.6
Stock Data	VOLT IN
52-week High (Rs)	1,946
F2 wook Low (Do)	1 1 2 5

52-week Low (Rs)	1,135
Shares outstanding (mn)	330.9
Market-cap (Rs bn)	405
Market-cap (USD mn)	4,721
Net-debt, FY25E (Rs mn)	0.0
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	2,802.9
ADTV-3M (USD mn)	32.7
Free float (%)	69.7
Nifty-50	24,273.8
INR/USD	85.7

### Shareholding, Mar-25

Promoters (%)	30.3
FPIs/MFs (%)	22.0/33.2

Price Performance									
(%)	1M	3M	12M						
Absolute	(7.4)	(11.6)	(7.3)						
Rel. to Nifty	(14.0)	(14.2)	(14.8)						

#### 1-Year share price trend (Rs)



#### Chirag Jain

*chirag.jain@emkayglobal.com* +91-22-66242428

#### Jaimin Desai

*jaimin.desai@emkayglobal.com* +91-22-66121334

#### Nandan Pradhan

nandan.pradhan@emkayglobal.com +91-22-66121238

#### Omkar Rane

omkar.rane@emkayglobal.com +91-22-66242414

#### Marazbaan Dastur

marazbaan.dastur@emkayglobal.com

# **Story in Charts**

Exhibit 1: Quarterly Summary – Voltas posted healthy ~13/54% YoY/QoQ revenue growth in Q4, with EBITDA margin at 7% (vs 4.5% in Q4FY24)

(Rs mn)	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	YoY (%)	QoQ (%)	FY24	FY25	YoY (%)
Revenue	42,029	49,210	26,191	31,051	47,676	13	54	1,24,812	1,54,128	23
Raw Material cost	33,727	38,922	19,421	23,807	37,454	11	57	98,140	1,19,604	22
as % of sales	80.2	79.1	74.2	76.7	78.6			78.6	77.6	
Employee Cost	1,992	2,023	2,382	2,311	2,185	10	(5)	7,788	8,901	14
as % of sales	4.7	4.1	9.1	7.4	4.6			6.2	5.8	
Other operating expenses	4,404	4,027	2,766	2,959	4,709	7	59	14,138	14,462	2
as % of sales	10.5	8.2	10.6	9.5	9.9			11.3	9.4	
Total Expenditure	40,123	44,972	24,569	29,077	44,348	11	53	1,20,066	1,42,966	19
EBITDA	1,906	4,238	1,622	1,974	3,328	75	69	4,746	11,162	135
Depreciation	118	134	164	179	141	19	(21)	476	618	30
EBIT	1,788	4,104	1,458	1,795	3,187	78	78	4,270	10,544	147
Other Income	544	803	1,055	591	797	46	35	2,533	3,245	28
Interest	208	98	136	155	233	12	50	559	621	11
Exceptional	-	-	-	-	-			-	-	
РВТ	2,124	4,809	2,377	2,231	3,751	77	68	6,244	13,168	111
Tax	634	1,165	726	599	1,075	69	80	2,371	3,565	50
PAT before MI	1,490	3,644	1,651	1,632	2,677	80	64	3,873	9,603	148
Minority interest	(325)	(301)	(311)	(311)	(266)	(18)	(14)	(1,347)	(1,189)	(12)
PAT	1,164	3,342	1,340	1,321	2,410	107	82	5,220	10,792	107

(%)	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	YoY (bps)	QoQ (bps)	FY24	FY25	YoY (bps)
Gross margin	19.8	20.9	25.8	23.3	21.4	169	(189)	21.4	22.4	103
EBITDAM	4.5	8.6	6.2	6.4	7.0	245	62	3.8	7.2	344
EBITM	4.3	8.3	5.6	5.8	6.7	243	90	3.4	6.8	342
EBTM	5.1	9.8	9.1	7.2	7.9	281	69	5.0	8.5	354
PATM	2.8	6.8	5.1	4.3	5.1	228	80	4.2	7.0	282
Effective Tax rate	29.9	24.2	30.5	26.8	28.7	(122)	181	38.0	27.1	(1,090)

Source: Company, Emkay Research


This report is intended for Team White Margue Solutions (team.emkay@whitemarguesolutions.com) use and downloaded

Exhibit 2: Segmental Mix – Unitary Products (UCP) saw higher growth (17% YoY), with a positive surprise on margins at 10%; EMP division was softer (~4% YoY) while margins saw a decline after 3 consecutive quarters of profitability

Particulars (Rs mn)	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	YoY (%)	QoQ (%)	FY24	FY25	YoY (%)
EMPS	10,979	9,491	8,799	11,902	11,375	4	(4)	36,830	41,568	13
YoY (%)	47	40	-5	21	4					
Professional electronics and industrial systems	1,564	1,608	1,467	1,297	1,321	(16)	2	5,879	5,692	(3)
YoY (%)	10	13	9	-16	-16					
Unitary Products	29,551	38,022	15,822	17,711	34,584	17	95	81,605	1,06,139	30
YoY (%)	44	51	31	19	17					
Total Sales	42,094	49,121	26,088	30,910	47,280	12	53	124,314	153,400	23
PBIT										
EMPS	-1077	675	462	567	-17	(98)	(103)	-3,285	1,686	(151)
Professional electronics and industrial systems	478	448	396	368	341	(29)	(7)	2,057	1,553	(24)
Unitary Products	2704	3270	1162	1043	3448	27	231	6,935	8,923	29
Total PBIT	2,105	4,394	2,020	1,978	3,771	79	91	5,707	12,163	113
Finance Costs	208	98	136	155	233	12	50	559	621	11
Unallocable expense	(227)	(513)	(492)	(408)	(213)	(6)	(48)	(1,096)	(1,626)	48
as a % of sales	(0.5)	(1.0)	(1.9)	(1.3)	(0.5)					
Loss from JVs	(383)	(294)	(323)	(324)	(320)			(1,386)	(1,260)	(9)
Exceptional Items	-	-	-	-	-					
РВТ	1,741	4,515	2,054	1,906	3,432	97	80	4,858	11,908	
PBIT margin (%)	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	YoY (bps)	QoQ (bps)	FY24	FY25	YoY (bps)
EMPS	(9.8)	7.1	5.2	4.8	(0.2)	966	(492)	(8.9)	4.1	1,298
Professional electronics and industrial systems	30.6	27.9	27.0	28.4	25.8	(478)	(260)	35.0	27.3	(770)
Unitary Products	9.2	8.6	7.3	5.9	10.0	82	408	8.5	8.4	(9)
Total PBIT	5.0	8.9	7.7	6.4	8.0	297	158	4.6	7.9	334


Source: Company, Emkay Research






Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team.emkav@whitemarguesolutions.com) use and downloaded




Source: Company, Emkay Research

Exhibit 6: EMPS revenue growth was softer in Q4 at 3.6% YoY growth...




Source: Company, Emkay Research






Source: Company, Emkay Research

Exhibit 5: ...which, coupled with better product mix and scale benefits, has led to a spike in UCP EBIT margins to  ${\sim}10\%$ 




Source: Company, Emkay Research

Exhibit 7: ...while Rs400mn provisioning (international project delays) during the quarter ate into steady-state EMPS EBIT margins



Source: Company, Emkay Research

Exhibit 9: ...while EBIT margins were also soft, at 25.8%



Source: Company, Emkay Research

This report is intended for reall white margue solutions (team.enkay@whitemarquesolutions.com) use and downloa

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 10: Voltas – Revenue Model

(Rs mn)	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Revenue	75,558	79,345	94,988	124,812	154,128	164,731	184,475
Growth YoY (%)	-1.3	5.0	19.7	31.4	23.5	6.9	12.0
UCP (RAC, Com Ref/AC & Air Cooler)	42,185	48,819	64,745	81,605	106,139	116,393	132,428
Growth YoY (%)	3.6	15.7	32.6	26.0	30.1	9.7	13.8
EMPS (Projects)	28,786	24,705	24,029	36,830	41,568	41,590	44,794
Growth YoY (%)	-11.3	-14.2	-2.7	53.3	12.9	0.1	7.7
EPS (Products - Mining & Textile)	3,595	4,887	5,220	5,879	5,692	6,091	6,517
Growth YoY (%)	8.4	35.9	6.8	12.6	-3.2	7.0	7.0
Gross profit	19,773	20,378	21,206	26,672	34,524	36,899	41,322
Gross margin (%)	26.2	25.7	22.3	21.4	22.4	22.4	22.4
EBITDA	6,414	6,815	5,724	4,746	11,162	11,814	13,701
EBITDA margin (%)	8.5	8.6	6.0	3.8	7.2	7.2	7.4
Depreciation	338.9	372.6	396.2	475.9	617.8	845.9	1,074.8
EBIT	6,075	6,443	5,328	4,270	10,544	10,969	12,627
Growth YoY (%)	-7.2	6.1	-17.3	-19.8	146.9	4.0	15.1
EBIT margin (%)	8.0	8.1	5.6	3.4	6.8	6.7	6.8
UCP (RAC, Com Ref/AC & Air Cooler)	5,837	5,134	5,378	6,935	8,923	9,079	10,462
EBIT margin (%)	13.8	10.5	8.3	8.5	8.4	7.8	7.9
Growth YoY (%)	14.0	-12.0	4.8	28.9	28.7	1.7	15.2
EMPS (Projects)	270.1	1,257.7	-582.3	-3,284.9	1,686.4	1,954.7	2,239.7
EBIT margin (%)	0.9	5.1	-2.4	-8.9	4.1	4.7	5.0
Growth YoY (%)	-84.1	365.6	-146.3	464.1	-151.3	15.9	14.6
EPS (Products - Mining & Textile)	1,143	1,579	2,007	2,057	1,553	1,645	1,760
EBIT margin (%)	31.8	32.3	38.5	35.0	27.3	27.0	27.0
Growth YoY (%)	15.2	38.1	27.1	2.5	-24.5	5.9	7.0
Other Income	1,889	1,892	1,685	2,533	3,245	3,447	3,781
Interest	262	259	296	559	621	805	857
PBT before Exceptional Item	7,702	8,076	6,716	6,244	13,168	13,611	15,550
Exceptional Item	-	-	(2,438)	-	-	-	-
РВТ	7,702	8,076	4,278	6,244	13,168	13,611	15,550
Tax rate (%)	23.4	23.7	40.0	38.1	27.1	25.0	25.0
PAT before MI	5,898	6,163	2,569	3,867	9,603	10,208	11,663
Minority Interest	-36.5	-19.1	-12.1	38.9	70.9	70.9	70.9
Share of profit/(loss) of joint ventures (net of tax)	-610	-1,103	-1,207	-1,386	-1,260	-873	-533
Adj. PAT	5,251	5,041	3,789	2,520	8,414	9,406	11,200
PAT margin (%)	7.0	6.4	4.0	2.0	5.5	5.7	6.1
Growth YoY (%)	-7.6	-4.0	-24.8	-33.5	233.9	11.8	19.1
No of shares (mn)	330.8	330.8	330.8	330.8	330.8	330.8	330.8
EPS (Rs)	15.9	15.2	11.5	7.6	25.4	28.4	33.9

Source: Company, Emkay Research

# Exhibit 11: Actuals vs Estimates

Rs mn Q4FY25					FY25					
	Actual	Emkay Est	Var %	Consensus	Var %	Actual	Emkay Est	Var %	Consensus	Var %
Revenue	47,676	48,998	(2.7)	48,731	(2.2)	154,128	155,451	(0.9)	155,139	(0.7)
EBIT	3,187	3,501	(9.0)	3,697	(13.8)	10,544	10,858	(2.9)	11,006	(4.2)
PAT	2,410	2,626	(8.2)	2,641	(8.7)	8,414	8,629	(2.5)	8,605	(2.2)

Source: Company, Emkay Research

## **Exhibit 12: Revision in Estimates**

(Rs mn)	FY	25	FY26E				FY27E			
	Actual	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY
Revenue	154,128	23.5	174,640	164,731	(5.7)	6.9	200,711	184,475	(8.1)	12.0
EBIT	10,544	146.9	12,348	10,969	(11.2)	4.0	14,310	12,627	(11.8)	15.1
EBIT margin (%)	6.8	342 bps	7.1	6.7	(41) bps	(18) bps	7.1	6.8	(28) bps	19 bps
Adj PAT	8,413.7	233.9	10,312.2	9,405.6	(8.8)	11.8	12,371.9	11,200.0	(9.5)	19.1


Source: Company, Emkay Research

# Exhibit 13: SOTP-based Valuation

(Rs mn)	Mar-27E PAT	PER (x)	Market Capitalization	Contribution to SOTP (%)
UCP	8,437	50	4,21,850	87.7
EMPS	1,806	15	27,090	5.6
EPS (Rs)	1,419	15	21,285	4.4
Total MCAP	11,662		4,70,225	
Number of Shares			331	
Target Price (Rs)			1,421	
Value of VoltBek at P/sales of 0.75x (Rs)			33	2.2
Total Value (Rs)		41	1,450	100


Source: Company, Emkay Research

Exhibit 14: We build in revenue CAGR of 9% over FY25-27E...




Source: Company, Emkay Research

Exhibit 16: PAT to see steady-state improvement given operating leverage from robust UCP growth and normalization of project margins, coupled with improving product mix...




Source: Company, Emkay Research





Source: Company, Emkay Research

Exhibit 17: ...leading to mid-teen RoE/RoCE for Voltas




Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team.emkay@whitemarguesolutions.com) use and downloaded

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.






Source: Company, Emkay Research


Exhibit 19: Voltas's implied UCP P/E is trading at its 10Y average UCP P/E of 44x

Voltas' Implied UCP - P/E Band (x)



Source: Company, Emkay Research

# Exhibit 20: The stock currently trades at ~42x 1Y Fwd PER below its 10Y Average



Source: Company, Emkay Research

# **Voltas: Consolidated Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	94,988	124,812	154,128	164,731	184,475
Revenue growth (%)	19.7	31.4	23.5	6.9	12.0
EBITDA	5,724	4,746	11,162	11,814	13,701
EBITDA growth (%)	(16.0)	(17.1)	135.2	5.8	16.0
Depreciation & Amortization	396	476	618	846	1,075
EBIT	5,328	4,270	10,544	10,969	12,627
EBIT growth (%)	(17.3)	(19.8)	146.9	4.0	15.1
Other operating income	-	-	-	-	
Other income	1,685	2,533	3,245	3,447	3,781
Financial expense	296	559	621	805	857
РВТ	6,716	6,244	13,168	13,611	15,550
Extraordinary items	(2,438)	0	0	0	0
Taxes	1,709	2,377	3,565	3,403	3,888
Minority interest	(12)	39	71	71	71
Income from JV/Associates	(1,207)	(1,386)	(1,260)	(873)	(533)
Reported PAT	1,350	2,520	8,414	9,406	11,200
PAT growth (%)	(73.2)	86.6	233.9	11.8	19.1
Adjusted PAT	3,789	2,520	8,414	9,406	11,200
Diluted EPS (Rs)	11.5	7.6	25.4	28.4	33.9
Diluted EPS growth (%)	(24.8)	(33.5)	233.9	11.8	19.1
DPS (Rs)	5.5	4.3	5.5	7.0	7.0
Dividend payout (%)	135.4	56.8	21.6	24.6	20.7
EBITDA margin (%)	6.0	3.8	7.2	7.2	7.4
EBIT margin (%)	5.6	3.4	6.8	6.7	6.8
Effective tax rate (%)	25.4	38.1	27.1	25.0	25.0
NOPLAT (pre-IndAS)	3,972	2,645	7,690	8,226	9,470
Shares outstanding (mn)	331	331	331	331	331

Balance Sheet					
	5.00	5.04	=) (0 =	EV:06E	
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Share capital	331	331	331	331	331
Reserves & Surplus	54,190	57,874	64,802	71,821	80,634
Net worth	54,521	58,205	65,133	72,152	80,965
Minority interests	417	337	271	271	271
Non-current liab. & prov.	(303)	176	140	140	140
Total debt	6,160	7,133	8,633	11,115	11,684
Total liabilities & equity	61,140	66,154	74,462	83,963	93,345
Net tangible fixed assets	4,105	4,351	8,638	11,489	14,442
Net intangible assets	62	56	34	19	4
Net ROU assets	357	348	340	330	317
Capital WIP	983	3,675	824	1,053	1,303
Goodwill	723	723	723	723	723
Investments [JV/Associates]	11,610	14,385	2,070	2,070	2,070
Cash & equivalents	26,560	29,221	37,145	41,059	44,700
Current assets (ex-cash)	58,035	67,186	81,304	87,038	95,894
Current Liab. & Prov.	41,294	53,790	56,614	59,818	66,107
NWC (ex-cash)	16,741	13,396	24,689	27,220	29,787
Total assets	61,140	66,154	74,462	83,963	93,345
Net debt	(20,401)	(22,088)	(28,512)	(29,944)	(33,016)
Capital employed	61,140	66,154	74,462	83,963	93,345
Invested capital	21,631	18,526	34,084	39,451	44,956
BVPS (Rs)	164.8	176.0	196.9	218.1	244.8
Net Debt/Equity (x)	(0.4)	(0.4)	(0.4)	(0.4)	(0.4)
Net Debt/EBITDA (x)	(3.6)	(4.7)	(2.6)	(2.5)	(2.4)
Interest coverage (x)	23.7	12.2	22.2	17.9	19.1
RoCE (%)	8.9	6.7	15.1	13.9	14.3

Source: Company, Emkay Research

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
PBT (ex-other income)	3,071	4,858	11,908	12,737	15,017
Others (non-cash items)	3,323	3,036	(1,349)	(3,447)	(3,781)
Taxes paid	(1,656)	(2,115)	(3,107)	(3,403)	(3,888)
Change in NWC	(3,836)	801	(10,932)	(2,530)	(2,567)
Operating cash flow	1,594	7,615	(2,241)	5,008	6,713
Capital expenditure	(1,774)	(2,883)	(1,907)	(3,902)	(4,249)
Acquisition of business	-	-	-	-	-
Interest & dividend income	706	835	1,309	3,447	3,781
Investing cash flow	(816)	(5,224)	1,579	(455)	(469)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	2,728	974	1,500	2,482	569
Payment of lease liabilities	-	-	-	-	-
Interest paid	(284)	(555)	(610)	(805)	(857)
Dividend paid (incl tax)	(1,829)	(1,432)	(1,820)	(2,316)	(2,316)
Others	(65)	(149)	(67)	0	0
Financing cash flow	550	(1,163)	(997)	(639)	(2,605)
Net chg in Cash	1,328	1,228	(1,659)	3,915	3,640
OCF	1,594	7,615	(2,241)	5,008	6,713
Adj. OCF (w/o NWC chg.)	5,430	6,814	8,690	7,539	9,280
FCFF	(181)	4,732	(4,149)	1,106	2,464
FCFE	229	5,008	(3,460)	3,748	5,387
OCF/EBITDA (%)	27.8	160.4	(20.1)	42.4	49.0
FCFE/PAT (%)	17.0	198.7	(41.1)	39.9	48.1
FCFF/NOPLAT (%)	(4.5)	178.9	(53.9)	13.4	26.0

Source: Company, Emkay Research

Valuations and key Ratios Y/E Mar FY24 FY25 FY26E FY27E FY23 P/E (x) 106.8 160.6 48.1 43.0 36.1 EV/CE(x) 6.3 5.8 5.1 4.5 4.0 P/B (x) 7.4 7.0 6.2 5.6 5.0 4.0 2.4 2.3 2.0 EV/Sales (x) 3.1 EV/EBITDA (x) 67.1 80.6 33.7 31.7 27.1 EV/EBIT(x) 72.1 89.6 35.7 34.2 29.4 EV/IC (x) 17.8 20.6 9.5 11.0 8.3 FCFF yield (%) 1.2 0.3 0.7 (1.1)FCFE yield (%) 0.1 1.2 (0.9) 0.9 1.3 Dividend yield (%) 0.5 0.4 0.4 0.6 0.6 DuPont-RoE split Net profit margin (%) 4.0 2.0 5.5 5.7 6.1 Total asset turnover (x) 1.6 2.0 2.2 2.1 2.1 Assets/Equity (x) 1.1 1.1 1.1 1.1 1.2 RoE (%) 13.6 6.9 4.5 13.7 14.6 DuPont-RoIC NOPLAT margin (%) 4.2 2.1 5.0 5.0 5.1 IC turnover (x) 5.0 6.2 5.9 4.5 4.4 RoIC (%) 21.1 13.2 29.2 22.4 22.4 **Operating metrics** Core NWC days 64.3 39.2 58.5 60.3 58.9 Total NWC days 64.3 39.2 58.5 60.3 58.9 Fixed asset turnover 12.5 14.6 13.5 10.4 9.4 Opex-to-revenue (%) 16.3 17.6 15.2 15.2 15.0

Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team.emkav@whitemarguesolutions.com) use and downloade

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY – DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
07-Apr-25	1,295	1,600	Buy	Chirag Jain

# **RECOMMENDATION HISTORY - TREND**



Source: Company, Emkay Research

is report is intended for Team White Margue Solutions (team.emkav@whitemarguesolutions.com) use and downloaded

# GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

# COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 09, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

## Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of May 09, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 09, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

## **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

# Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.